PL1468697T3 - Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań - Google Patents

Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań

Info

Publication number
PL1468697T3
PL1468697T3 PL04076075T PL04076075T PL1468697T3 PL 1468697 T3 PL1468697 T3 PL 1468697T3 PL 04076075 T PL04076075 T PL 04076075T PL 04076075 T PL04076075 T PL 04076075T PL 1468697 T3 PL1468697 T3 PL 1468697T3
Authority
PL
Poland
Prior art keywords
injection
compositions containing
tazobactam
useful
containing piperacillin
Prior art date
Application number
PL04076075T
Other languages
English (en)
Inventor
Jonathan Marc Cohen
Syed Muzafar Shah
Christian Luther Ofslager
Mahdi Bakir Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1468697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PL1468697T3 publication Critical patent/PL1468697T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04076075T 2003-04-14 2004-04-06 Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań PL1468697T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46280803P 2003-04-14 2003-04-14
EP04076075A EP1468697B1 (en) 2003-04-14 2004-04-06 Compositions containing piperacillin and tazobactam useful for injection

Publications (1)

Publication Number Publication Date
PL1468697T3 true PL1468697T3 (pl) 2008-05-30

Family

ID=32326726

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04076075T PL1468697T3 (pl) 2003-04-14 2004-04-06 Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań

Country Status (34)

Country Link
US (3) US7498312B2 (pl)
EP (1) EP1468697B1 (pl)
JP (1) JP4644659B2 (pl)
KR (1) KR100824554B1 (pl)
CN (1) CN1802179B (pl)
AR (1) AR043863A1 (pl)
AT (1) ATE381947T1 (pl)
AU (1) AU2004229407B2 (pl)
BR (1) BRPI0409450B8 (pl)
CA (1) CA2464258C (pl)
CH (1) CH695185A9 (pl)
CL (1) CL2004000782A1 (pl)
CO (1) CO5700796A2 (pl)
CR (2) CR8035A (pl)
CY (1) CY1108064T1 (pl)
DE (1) DE602004010862T2 (pl)
DK (1) DK1468697T3 (pl)
EC (1) ECSP056100A (pl)
ES (1) ES2298672T3 (pl)
FR (1) FR2853547B1 (pl)
GB (1) GB2400557B (pl)
IL (1) IL171337A (pl)
MX (1) MXPA05010996A (pl)
MY (1) MY139099A (pl)
NO (1) NO20054789L (pl)
NZ (1) NZ543005A (pl)
PL (1) PL1468697T3 (pl)
PT (1) PT1468697E (pl)
RU (2) RU2322980C2 (pl)
SA (1) SA04250119B1 (pl)
SI (1) SI1468697T1 (pl)
TW (1) TWI308069B (pl)
WO (1) WO2004091666A1 (pl)
ZA (1) ZA200508315B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1589901A4 (en) * 2002-12-20 2006-08-09 Generipharm Inc INTRAKUTANE INJECTION
PL1468697T3 (pl) * 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań
JP2008516967A (ja) * 2004-10-14 2008-05-22 ワイス 乳酸ナトリウム希釈液中にピペラシリン、タゾバクタムおよびアミノカルボン酸を含む組成物
RS51506B (sr) * 2004-12-02 2011-06-30 Venus Remedies Limited H. O&R&D. Smeše za suzbijanje beta-laktamazom posredovane rezistencije na antibiotike upotrebom inhibitora beta-laktamaze, korisne za injekcije
ES2284318B1 (es) * 2005-04-13 2008-11-01 Labiana Development, S.L. Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it) * 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN102441169A (zh) * 2006-08-25 2012-05-09 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN1927201B (zh) * 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN102210679B (zh) * 2006-08-25 2013-03-13 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
EA030662B1 (ru) 2010-11-25 2018-09-28 Аллекра Терапойтикс Гмбх β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ
WO2012122535A2 (en) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP6117811B2 (ja) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド 糖尿病を処置するための製剤
MY169816A (en) 2012-03-26 2019-05-16 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) * 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
KR102329764B1 (ko) 2013-03-15 2021-11-23 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및/또는 피하 주사를 위한 주사기, 키트, 및 방법
CN106714799A (zh) * 2014-10-08 2017-05-24 泽井制药株式会社 冷冻干燥制剂的制造方法
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
MX2017013433A (es) * 2016-03-31 2018-01-30 Wockhardt Ltd Composiciones antibacterianas.
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
CN117085022A (zh) 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
US11110054B2 (en) * 2018-05-09 2021-09-07 Slayback Pharma Llc Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法
IL309404A (en) * 2021-06-16 2024-02-01 Auregen Biotherapeutics Sa Gellan gum compositions and method for their preparation
WO2025253343A1 (en) * 2024-06-06 2025-12-11 Chandan Chopra AN ANTIBIOTIC COMPOSITION OF A PENICILLIN, A β-LACTAMASE INHIBITOR AND AN ION-CHELATING AGENT
CN119367287B (zh) * 2024-12-27 2025-03-28 成都硕德药业有限公司 一种重酒石酸去甲肾上腺素注射液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534977A (en) * 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4477452A (en) * 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US5763480A (en) * 1994-02-14 1998-06-09 The Jewish Hospital Of St. Louis Inhibitors of cell-medicated disorders
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
EP1499341A4 (en) * 2002-04-18 2010-10-27 Univ Iowa Res Found METHOD FOR INHIBITING AND TREATING BACTERIAL BIOFILMS WITH METAL CHELATE IMAGES
US6900184B2 (en) * 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
PL1468697T3 (pl) 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań

Also Published As

Publication number Publication date
CR9792A (es) 2008-09-23
CO5700796A2 (es) 2006-11-30
SI1468697T1 (sl) 2008-04-30
TW200503758A (en) 2005-02-01
MXPA05010996A (es) 2005-12-12
CH695185A5 (fr) 2006-01-13
CN1802179B (zh) 2011-09-14
NZ543005A (en) 2009-03-31
ES2298672T3 (es) 2008-05-16
WO2004091666A1 (en) 2004-10-28
KR100824554B1 (ko) 2008-04-24
EP1468697B1 (en) 2007-12-26
RU2005135135A (ru) 2006-06-10
BRPI0409450A (pt) 2006-05-02
RU2322980C2 (ru) 2008-04-27
CY1108064T1 (el) 2014-02-12
US7915229B2 (en) 2011-03-29
PT1468697E (pt) 2008-03-05
GB2400557A (en) 2004-10-20
ZA200508315B (en) 2008-04-30
FR2853547A1 (fr) 2004-10-15
DK1468697T3 (da) 2008-04-14
DE602004010862T2 (de) 2009-01-02
CA2464258A1 (en) 2004-10-14
AR043863A1 (es) 2005-08-17
TWI308069B (en) 2009-04-01
IL171337A (en) 2011-03-31
ATE381947T1 (de) 2008-01-15
AU2004229407B2 (en) 2010-04-22
SA04250119B1 (ar) 2008-03-30
HK1069775A1 (en) 2005-06-03
RU2007142454A (ru) 2009-05-27
US20110166091A1 (en) 2011-07-07
CH695185A9 (fr) 2006-02-28
GB2400557B (en) 2005-06-15
NO20054789D0 (no) 2005-10-18
BRPI0409450B8 (pt) 2021-05-25
EP1468697A1 (en) 2004-10-20
KR20060014375A (ko) 2006-02-15
BRPI0409450B1 (pt) 2016-07-12
US7498312B2 (en) 2009-03-03
CA2464258C (en) 2005-06-07
GB0407853D0 (en) 2004-05-12
ECSP056100A (es) 2006-03-01
JP4644659B2 (ja) 2011-03-02
NO20054789L (no) 2005-12-13
MY139099A (en) 2009-08-28
US20090176720A1 (en) 2009-07-09
AU2004229407A1 (en) 2004-10-28
US20060234995A1 (en) 2006-10-19
DE602004010862D1 (de) 2008-02-07
WO2004091666A8 (en) 2005-11-10
JP2006523695A (ja) 2006-10-19
CL2004000782A1 (es) 2005-03-04
US8133883B2 (en) 2012-03-13
CN1802179A (zh) 2006-07-12
CR8035A (es) 2006-05-30
FR2853547B1 (fr) 2006-08-04

Similar Documents

Publication Publication Date Title
GB2400557B (en) Compositions containing piperacillin and tazobactam useful for injection
AU2003230899A1 (en) Compositions containing piperacillin and tazobactam useful for injection
IL173639A0 (en) Ppar-activating compound and pharmaceutical composition containing same
AP2089A (en) Compositions and methods for combination antiviraltherapy
EP1701691A4 (en) METHODS AND COMPOSITIONS FOR ORAL HYGIENE
KR100984939B9 (ko) 발사르탄 및 nep 저해제를 포함하는 제약학적 조성물
AU2003220205A8 (en) Ethanol-diesel fuel composition and methods thereof
EP1628967A4 (en) IMMUNE REPRESENTING COMPOUNDS AND COMPOSITIONS
LT1633336T (lt) Imunosupresiniai junginiai ir kompozicijos
EP1644367A4 (en) IMMUNE REPRESENTING COMPOUNDS AND COMPOSITIONS
IL197889A (en) Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same
AU2003267644A8 (en) Dental compositions and methods
AU2003256805A8 (en) Compounds compositions and methods
AU2003287443A8 (en) Compositions and methods for pain reduction
GB0326520D0 (en) Molluscicidal and anti-barnacle compounds
IL171902A0 (en) Compositions comprising gastrin compounds and their use in diabetes
SG122811A1 (en) Fuel additive composition and fuel composition containing the same
PL365602A1 (pl) Kompozycje farmaceutyczne i sposoby ich stosowania
IL153897A0 (en) Pharmaceutical compositions and methods for use
IL173626A0 (en) Small peptides and oral pharmaceutical compositions containing the same
EP1608970A4 (en) CCN3 COMPOSITIONS AND METHODS
ZA200601232B (en) 3-Aryl-4-hydroxyfuranone compounds and pharmaceutical and veterinary compositions containing them
GB0304508D0 (en) Antiperspirant actives and compositions
SI1661890T1 (sl) Spojina, ki aktivira PPAR, in farmacevtski sestavek, ki jo vsebuje
AU2003220601A8 (en) Synergistic l-methadone compositions and methods of use thereof